US biotech major Gilead Sciences (Nasdaq: GILD) recorded sales of $7.32 billion for the fourth-quarter of 2016, down 14.2% from $8.41 billion in the like year-earlier period but just beating analysts’ expectations of $7.2 billion.
Net income reached $3.12 billion, down 33.6% versus $4.68 billion in the fourth quarter of the previous year. Diluted earnings per share were $2.34 versus $3.19 and non-generally accepted accounting principles (GAAP) EPS at $2.70 versus $3.32.
Gilead shares fell 5.32% to $73.13 in after-hours trading on Tuesday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze